FXR affects liver metabolism, inflammation, and liver fibrosis as a key component of NASH, and reduces portal hypertension and liver fibrosis in NASH rats (Schwabl et al., 2021). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.